NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Enanta Pharmaceuticals Inc. ENTA
15 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
USD 65.3M
Revenue, FY2025 · full 15-year series below
Revenue $M
Net income $M
FY2025 · Revenue 65.3 · Net income -81.9
Compound annual growth
Revenue compounded at −11.8% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−125 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -130.7% · Net -125.4%
ROE
FY2025 · ROE -84.6%
Each USD of equity lost 85 cents this year.
The 15-year record
15 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | 0.1 | 0.1 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 |
| EBITDA $B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Income tax $B | −0.0 | −0.0 | 0.0 | −0.0 | −0.0 | 0.0 | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | 0.0 | 0.0 | 0.0 |
| Net income $B | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 |
| Free cash flow $B | −0.0 | −0.1 | −0.1 | −0.1 | −0.1 | 0.0 | 0.1 | 0.0 | 0.1 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 |
| EPS, diluted $ | −3.84 | −5.48 | −6.38 | −5.91 | −3.92 | −1.81 | 2.21 | 3.48 | 0.91 | 1.13 | 4.09 | 1.80 | −0.67 | 1.13 | 1.32 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | −84.6 | −67.2 | −49.7 | −33.8 | −18.5 | −7.9 | 10.8 | 20.7 | 6.2 | 8.6 | 41.1 | 26.6 | · | · | · |
| Shares out B | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.00 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 58 reconciliationsAUDITED
Reconciled in 15 of 19 fiscal years. 18 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated innot stated in the filings
Fiscal year endsSeptember 30
SEC categorysmaller reporting company
Data on record since2011